SciELO - Scientific Electronic Library Online

 
vol.14 issue1-2La ecografía fetal: Análisis de dos años en el Hospital Nacional de Niños de Costa RicaFVII polymorphisms IVS7, FVII R353Q in FVII gene and FXIII Val34Leu and its association with the risk of acute myocardial infartion in Costa Rica Patients author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Costarricense de Cardiología

Print version ISSN 1409-4142

Abstract

SALAZAR-SANCHEZ, Lizbeth et al. The importance of the determination of Factor X acivated for anticoagulation with low molecular weight heparins experience at the Hospital San Juan de Dios. (First report) 2009-2011. Rev. costarric. cardiol [online]. 2012, vol.14, n.1-2, pp.09-13. ISSN 1409-4142.

Anticoagulation is an important therapeutic tool for patients with thromboembolic disease who receive therapy with low molecular weight heparins (LMWH). This report gives evidence about the importance of determining the activity of Anti-Xa activity for monitoring enoxaparin and for identifying those patients who need this analysis based on some risk factors. Methods: We studied 34 adult patients who received enoxaparin as anticoagulation therapy during the period 2009- 2011. We performed a descriptive analysis of demographic and clinical characteristics of all patients, indicating the reasons for anticoagulation, comorbidities and type of anticoagulation. We determined the anti-Xa activity 4 hours after administration of enoxaparin. Results: The mean age of patients was 62,3 + 17,7 years, regardless of gender. 72,7% of patients received enoxaparin as therapy for an acute coronary syndrome. The most frequent comorbidity was hypertension. The average of renal clearance was 62,47 ml/min, only three patients had a renal clearance below 30 ml/min. 44,1% of the patients were obese. 55, 9% of patients were within therapeutic levels of anti Xa activity and 35,3% of patients had an anti-Xa activity considered as prophylactic. Conclusion: The management of adult patients receiving anticoagulation therapy with LMWH is complex and it is reflected in their demographic and clinical characteristics. It is important to determine Anti-Xa activity to monitor the use of enoxaparin as anticoagulant therapy because of the high variability found in certain groups of patients.

Keywords : anticoagulation; low molecular weight heparin; coronary syndrome; Anti-Xa activity.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License